

Josh Luring

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4460607/josh-luring-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

35
papers

2,312
citations

24
h-index

39
g-index

39
ext. papers

2,671
ext. citations

9.6
avg, IF

4.15
L-index

#	Paper	IF	Citations
35	Phase II Study of Taselisib in -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I.. <i>JCO Precision Oncology</i> , 2022 , 6, e2100424	3.6	1
34	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. <i>Journal of Clinical Investigation</i> , 2019 , 129, 4708-4723	15.9	21
33	Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. <i>Oncologist</i> , 2019 , 24, 146-150	5.7	2
32	PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 451-464	4.4	12
31	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 379-386	12.9	36
30	frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary mutant breast cancers. <i>Oncotarget</i> , 2017 , 8, 103415-103427	3.3	16
29	A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1495-1498	7.3	12
28	Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton. <i>Cell</i> , 2016 , 164, 433-46	56.2	203
27	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 993-9	12.9	129
26	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. <i>Oncotarget</i> , 2016 , 7, 6281-93	3.3	49
25	Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. <i>Oncotarget</i> , 2016 , 7, 4241-51	3.3	32
24	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. <i>Clinical Biochemistry</i> , 2015 , 48, 993-8	3.5	77
23	HER2 missense mutations have distinct effects on oncogenic signaling and migration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E6205-14	11.5	51
22	Engineering targeted chromosomal amplifications in human breast epithelial cells. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 313-21	4.4	2
21	NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 11583-8	11.5	17
20	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. <i>Oncotarget</i> , 2015 , 6, 25240-51	3.3	7
19	TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. <i>Oncotarget</i> , 2015 , 6, 44927-40	3.3	24

18	Detection of cancer DNA in plasma of patients with early-stage breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 2643-2650	12.9	280
17	MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 17606-11	11.5	46
16	Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. <i>Cancer Research</i> , 2013 , 73, 3248-61	10.1	31
15	PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. <i>Clinical Cancer Research</i> , 2013 , 19, 5413-22	12.9	67
14	The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 670-8	7.3	81
13	Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. <i>Oncotarget</i> , 2013 , 4, 29-34	3.3	33
12	The growth response to androgen receptor signaling in ER-negative human breast cells is dependent on p21 and mediated by MAPK activation. <i>Breast Cancer Research</i> , 2012 , 14, R27	8.3	48
11	NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. <i>Molecular Cell</i> , 2011 , 44, 609-20	17.6	285
10	BEAMing sheds light on drug resistance. <i>Clinical Cancer Research</i> , 2011 , 17, 7508-10	12.9	4
9	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 17773-8	11.5	111
8	Knockin of mutant PIK3CA activates multiple oncogenic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 2835-40	11.5	118
7	Tamoxifen-stimulated growth of breast cancer due to p21 loss. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 288-93	11.5	77
6	The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. <i>Blood</i> , 2008 , 111, 856-64	2.2	123
5	A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting. <i>Nature Protocols</i> , 2007 , 2, 2865-74	18.8	20
4	Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. <i>Cancer Research</i> , 2007 , 67, 8460-7	10.1	73
3	A conserved transcriptional enhancer regulates RAG gene expression in developing B cells. <i>Immunity</i> , 2003 , 19, 105-17	32.3	112
2	c-Myb binds to a sequence in the proximal region of the RAG-2 promoter and is essential for promoter activity in T-lineage cells. <i>Molecular and Cellular Biology</i> , 2000 , 20, 9203-11	4.8	43
1	Distinct factors regulate the murine RAG-2 promoter in B- and T-cell lines. <i>Molecular and Cellular Biology</i> , 1999 , 19, 2601-12	4.8	59

